Eaton Vance Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $30M | Buy |
112,246
+1,310
| +1% | +$278K | 0.04% | 360 |
|
|
2022
Q2 | $22.6M | Sell |
110,936
-3,936
| -3% | -$805K | 0.03% | 433 |
|
|
2022
Q1 | $24.2M | Sell |
114,872
-19,582
| -15% | -$4.26M | 0.03% | 461 |
|
|
2021
Q4 | $32.3M | Sell |
134,454
-6,995
| -5% | -$1.8M | 0.04% | 383 |
|
|
2021
Q3 | $39.5M | Sell |
141,449
-22,065
| -13% | -$7.23M | 0.06% | 306 |
|
|
2021
Q2 | $56.6M | Buy |
163,514
+26
| +0% | +$7.88K | 0.08% | 244 |
|
|
2021
Q1 | $45.7M | Buy |
163,488
+1,444
| +0.9% | +$389K | 0.07% | 278 |
|
|
2020
Q4 | $39.7M | Buy |
162,044
+8,802
| +6% | +$2.27M | 0.06% | 284 |
|
|
2020
Q3 | $43.5M | Sell |
153,242
-15,254
| -9% | -$4.25M | 0.08% | 230 |
|
|
2020
Q2 | $45.1M | Sell |
168,496
-5,174
| -3% | -$1.56M | 0.09% | 204 |
|
|
2020
Q1 | $54.9M | Buy |
173,670
+1,340
| +0.8% | +$407K | 0.13% | 147 |
|
|
2019
Q4 | $51.1M | Buy |
172,330
+1,410
| +0.8% | +$391K | 0.1% | 194 |
|
|
2019
Q3 | $39.8M | Sell |
170,920
-130,783
| -43% | -$30.5M | 0.09% | 208 |
|
|
2019
Q2 | $70.6M | Sell |
301,703
-6,273
| -2% | -$1.45M | 0.15% | 145 |
|
|
2019
Q1 | $72.8M | Sell |
307,976
-59,556
| -16% | -$18.8M | 0.17% | 135 |
|
|
2018
Q4 | $111M | Sell |
367,532
-81,109
| -18% | -$25.9M | 0.29% | 93 |
|
|
2018
Q3 | $159M | Buy |
448,641
+52
| +0% | +$17.9K | 0.35% | 84 |
|
|
2018
Q2 | $130M | Sell |
448,589
-296,205
| -40% | -$83.3M | 0.31% | 92 |
|
|
2018
Q1 | $204M | Buy |
744,794
+316,192
| +74% | +$98.1M | 0.25% | 106 |
|
|
2017
Q4 | $137M | Sell |
428,602
-19,771
| -4% | -$6.34M | 0.33% | 85 |
|
|
2017
Q3 | $140M | Buy |
448,373
+12,065
| +3% | +$3.57M | 0.36% | 80 |
|
|
2017
Q2 | $118M | Sell |
436,308
-24,032
| -5% | -$6.35M | 0.31% | 91 |
|
|
2017
Q1 | $126M | Sell |
460,340
-240,551
| -34% | -$68M | 0.34% | 84 |
|
|
2016
Q4 | $199M | Buy |
700,891
+205,238
| +41% | +$60.8M | 0.56% | 48 |
|
|
2016
Q3 | $155M | Buy |
495,653
+60,033
| +14% | +$17.8M | 0.45% | 65 |
|
|
2016
Q2 | $105M | Buy |
435,620
+309,401
| +245% | +$81.5M | 0.31% | 94 |
|
|
2016
Q1 | $32.9M | Sell |
126,219
-3,818
| -3% | -$1.01M | 0.1% | 165 |
|
|
2015
Q4 | $39.8M | Sell |
130,037
-198,751
| -60% | -$57.1M | 0.12% | 157 |
|
|
2015
Q3 | $95.9M | Sell |
328,788
-187,746
| -36% | -$62M | 0.3% | 90 |
|
|
2015
Q2 | $209M | Buy |
516,534
+71,929
| +16% | +$28.9M | 0.64% | 42 |
|
|
2015
Q1 | $188M | Buy |
444,605
+40,320
| +10% | +$15.9M | 0.57% | 55 |
|
|
2014
Q4 | $137M | Sell |
404,285
-59,394
| -13% | -$19.2M | 0.4% | 76 |
|
|
2014
Q3 | $153M | Buy |
463,679
+64,887
| +16% | +$21.4M | 0.46% | 68 |
|
|
2014
Q2 | $126M | Buy |
398,792
+73,864
| +23% | +$22.2M | 0.37% | 80 |
|
|
2014
Q1 | $99.4M | Buy |
324,928
+112,901
| +53% | +$35.8M | 0.29% | 98 |
|
|
2013
Q4 | $59.3M | Buy |
212,027
+103,909
| +96% | +$26.9M | 0.17% | 137 |
|
|
2013
Q3 | $26M | Buy |
108,118
+47,289
| +78% | +$10.6M | 0.08% | 180 |
|
|
2013
Q2 | $13.1M | Buy |
+60,829
| New | +$13M | 0.04% | 243 |
|
Other funds holding BIIB
Eaton Vance Management's BIIB Position: Q3 2022 in Review
Eaton Vance Management increased its Biogen (BIIB) stake by 1.2% in Q3 2022, buying an estimated $278K and bringing the position to 112,246 shares worth $30M. The position accounts for 0.04% of the portfolio, ranked #360.
Eaton Vance Management first reported a position in BIIB in Q2 2013 and has held it in 38 quarters since. The position peaked at $209M in Q2 2015. 986 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.
- Eaton Vance Management held 112,246 shares of Biogen worth $30M as of Q3 2022.
- Eaton Vance Management bought 1,310 Biogen shares in Q3 2022, an estimated $278K.
- Biogen made up 0.04% of Eaton Vance Management's portfolio in Q3 2022, its #360 holding.
- Eaton Vance Management first reported a position in Biogen in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's Biogen position peaked at $209M in Q2 2015.
- 986 funds tracked by Wall St. Rank held Biogen as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.